UBS Maintains Buy on Biogen, Raises Price Target to $300
UBS analyst Michael Yee maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $270 to $300.
Share
Why It Matters
An expert bank thinks Biogen is a good company to own. They raised how much they think the stock could be worth.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.